FERMT2 and pancreatic adenocarcinoma: Notably, increased FERMT2 expression may be linked to reduced disease-free survival (Fig. 1f(i)–1f(iii)), suggesting a potential role in chemoresistance or cancer recurrence, as suggested by ref. 40 Individual cancer analyses revealedFERMT1 as a prognostic marker in PAAD (p = 0.03, HR = 1.6) and SKCM (p < 0.001, HR = 1.7) (Supplementary Fig. 5).